| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Abrocitinib | Abrocitinib Impurity 1 | VE0011624 | View CAS 1622981-01-4 |
| Abrocitinib | Abrocitinib Impurity 2 | VE0011625 | View CAS 2744171-54-6 |
| Abrocitinib | Abrocitinib Impurity 3 | VE0011627 | View CAS 2744171-52-4 |
| Abrocitinib | Abrocitinib Related Compound 1 | VL5020002 | View CAS 1353501-22-0 |
| Abrocitinib | Abrocitinib Related Compound 2 | VL5020003 | View |
| Abrocitinib | Abrocitinib Related Compound 3 | VL5020004 | View |
Abrocitinib Related Compound
Abrocitinib is a kinase inhibitor that is used to treat individuals with moderate-to-severe atopic dermatitis.
References
- “U.S. FDA Approves Pfizer’s CIBINQO® (Abrocitinib) for Adults with Moderate-To Severe Atopic Dermatitis | Pfizer.” Pfizer.com, 2022, www.pfizer.com/news/press release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults.
- “Abrocitinib (Oral Route) Description and Brand Names – Mayo Clinic.” Mayoclinic.org, 2022, www.mayoclinic.org/drugs-supplements/abrocitinib-oral-route/description/drg 20529411.
- “Information for the Public | Abrocitinib, Tralokinumab or Upadacitinib for Treating Moderate to Severe Atopic Dermatitis | Guidance | NICE.” Nice.org.uk,NICE, 3 Aug. 2022, www.nice.org.uk/guidance/ta814/informationforpublic.
FAQ’s
What is the generic name for abrocitinib?
The US Food and Drug Administration has approved Pfizer’s CIBINQO® (abrocitinib) for adults with moderate-to-severe atopic dermatitis.
Which abrocitinib formulations are available on the market?
This medication available in the following dose forms: tablet.
Is abrocitinib available on the NHS?
The NHS provides abrocitinib (Cibinqo) and upadacitinib (Rinvoq). They are potential therapies for severe atopic dermatitis (eczema) in adults and adolescents aged 12 and above if at least one systemic immunosuppressant has not performed well enough if systemic immunosuppressants are ineffective.
